Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214Saul Kivimäe, Jonathan Zalevsky, Christie Fanton et al.|Cancer Research|2018Cited by 19
NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma ModelTakahiro Miyazaki, Jonathan Zalevsky, Saul Kivimäe et al.|Blood|2019Cited by 5
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Blood|2021Cited by 4
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Regular and Young Investigator Award Abstracts|2020Cited by 3
Abstract 3265: NKTR-255, a polymer-conjugated IL-15 enhances anti-tumor NK cell responses and synergizes with monoclonal antibodies to provide long-term survival in human lymphoma modelTakahiro Miyazaki, Jonathan Zalevsky, Saul Kivimäe et al.|Cancer Research|2019Cited by 0